{"id":77081,"date":"2026-08-28T21:17:51","date_gmt":"2026-08-28T13:17:51","guid":{"rendered":"https:\/\/flcube.com\/?p=77081"},"modified":"2026-08-28T21:37:23","modified_gmt":"2026-08-28T13:37:23","slug":"fosun-pharmas-velinotamig-wins-nmpa-conditional-approval-for-relapsed-or-refractory-multiple-myeloma","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=77081","title":{"rendered":"Fosun Pharma&#8217;s Velinotamig Wins NMPA Conditional Approval for Relapsed or Refractory Multiple Myeloma"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Shanghai Fosun Pharmaceutical (Group) Co., Ltd.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/beta\/quote\/600196:SHA\">SHA: 600196<\/a>, <a href=\"https:\/\/www.google.com\/finance\/beta\/quote\/2196:HKG\">HKG: 2196<\/a>) announced that <strong>velinotamig<\/strong> (project code: GR1803), a product licensed-in by its subsidiary <strong>YaoPharma<\/strong>, has been conditionally approved by the <strong>National Medical Products Administration (NMPA)<\/strong> for the treatment of adult patients with relapsed or refractory <strong>multiple myeloma (RRMM)<\/strong> who have previously received at least three prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody. The approval brings a T-cell-engaging bispecific option to one of hematologic oncology&#8217;s most difficult-to-treat, heavily pretreated populations.<\/p>\n\n\n\n<h2 id=\"h-regulatory-milestone\" class=\"wp-block-heading\">Regulatory Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Element<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td>Agency<\/td><td><strong>National Medical Products Administration (NMPA)<\/strong>, China<\/td><\/tr><tr><td>Approval Type<\/td><td>Conditional approval<\/td><\/tr><tr><td>Product<\/td><td><strong>Velinotamig (GR1803)<\/strong>, BCMA\u00d7CD3 bispecific antibody<\/td><\/tr><tr><td>Indication<\/td><td>Adults with relapsed or refractory <strong>multiple myeloma (RRMM)<\/strong> after \u22653 prior lines, incl. a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody<\/td><\/tr><tr><td>Date<\/td><td>27 Aug 2026<\/td><\/tr><tr><td>Licensee \/ MAH<\/td><td><strong>Yaopharma<\/strong>, subsidiary of <strong>Fosun Pharma<\/strong><\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-drug-profile-amp-mechanism-of-action\" class=\"wp-block-heading\">Drug Profile &amp; Mechanism of Action<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Molecule:<\/strong> <strong>Velinotamig (GR1803)<\/strong>, a <strong>BCMA\u00d7CD3<\/strong> bispecific antibody<\/li>\n\n\n\n<li><strong>Dual Targeting:<\/strong> Simultaneously targets both <strong>BCMA<\/strong> and <strong>CD3<\/strong> antigens<\/li>\n\n\n\n<li><strong>Mechanism:<\/strong> Redirects cytotoxic T cells to BCMA-expressing myeloma tumor cells and activates T cells to exert cytotoxic effects against the tumor cells<\/li>\n\n\n\n<li><strong>Class Positioning:<\/strong> T-cell-engaging bispecific, a modality demonstrating high response rates in triple-class-exposed myeloma patients with limited remaining options<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-licensing-structure\" class=\"wp-block-heading\">Licensing Structure<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Element<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td>Agreement Date<\/td><td>May 2026<\/td><\/tr><tr><td>Licensor<\/td><td><strong>Chongqing Genrix Bio<\/strong><\/td><\/tr><tr><td>Licensee<\/td><td><strong>Yaopharma<\/strong> (subsidiary of <strong>Fosun Pharma<\/strong>)<\/td><\/tr><tr><td>Licensed Rights<\/td><td>Exclusive clinical development and commercialization of <strong>Velinotamig<\/strong> injection in mainland China, Hong Kong, Macao, and Taiwan<\/td><\/tr><tr><td>Additional Rights<\/td><td>Exclusive process research and manufacturing<\/td><\/tr><tr><td>Regulatory Role<\/td><td><strong>Yaopharma<\/strong> serves as Marketing Authorization Holder (MAH) in the licensed territories<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p class=\"wp-block-paragraph\">Under the May 2026 license agreement with <strong>Chongqing Genrix Bio<\/strong>, <strong>Yaopharma<\/strong> obtained exclusive rights spanning clinical development, commercialization, process research, and manufacturing of <strong>Velinotamig<\/strong> injection across mainland China, Hong Kong, Macao, and Taiwan \u2014 and now serves as the product&#8217;s MAH. The swift progression from licensing to conditional approval underscores <strong>Fosun Pharma&#8217;s<\/strong> execution capability in in-licensing late-stage assets and driving them rapidly through the Chinese regulatory system.<\/p>\n\n\n\n<h2 id=\"h-market-impact-amp-outlook\" class=\"wp-block-heading\">Market Impact &amp; Outlook<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Triple-Class-Exposed Population:<\/strong> The indication targets patients who have exhausted proteasome inhibitors, immunomodulators, and anti-CD38 antibodies \u2014 a segment with poor prognosis where T-cell engagers are reshaping the treatment paradigm<\/li>\n\n\n\n<li><strong>BCMA Crowded-But-Growing Market:<\/strong> <strong>Velinotamig<\/strong> joins an expanding roster of BCMA-directed therapies in China, competing on efficacy depth, safety manageability, and commercial execution<\/li>\n\n\n\n<li><strong>Fosun Oncology Franchise:<\/strong> The approval strengthens <strong>Fosun Pharma&#8217;s<\/strong> (SHA: 600196, HKG: 2196) hematology-oncology portfolio and validates its in-licensing strategy as a route to pipeline depth<\/li>\n\n\n\n<li><strong>MAH Control:<\/strong> Holding full MAH rights across Greater China gives <strong>Yaopharma<\/strong> maximum pricing, distribution, and lifecycle flexibility in the licensed territories<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward\u2011Looking Statements<\/strong> \u2013 This brief contains forward-looking statements regarding regulatory conditions, commercialization, and market competition. Conditional approval may be subject to post-marketing confirmatory requirements. Actual results may differ materially. Not investment advice.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (SHA: 600196, HKG: 2196) announced that velinotamig (project code:&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7,11],"tags":[16,159,893,15,892,2790,3946],"class_list":["post-77081","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-cancer","tag-fosun-pharmaceutical","tag-hkg-2196","tag-product-approvals","tag-sha-600196","tag-t-cell-engager","tag-yaopharma"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v28.3) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Fosun Pharma&#039;s Velinotamig Wins NMPA Conditional Approval for Relapsed or Refractory Multiple Myeloma - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (SHA: 600196, HKG: 2196) announced that velinotamig (project code: GR1803), a product licensed-in by its subsidiary Yaopharma, has been conditionally approved by the National Medical Products Administration (NMPA) for the treatment of adult patients with relapsed or refractory multiple myeloma (RRMM) who have previously received at least three prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody. The approval brings a T-cell-engaging bispecific option to one of hematologic oncology&#039;s most difficult-to-treat, heavily pretreated populations.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=77081\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Fosun Pharma&#039;s Velinotamig Wins NMPA Conditional Approval for Relapsed or Refractory Multiple Myeloma\" \/>\n<meta property=\"og:description\" content=\"Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (SHA: 600196, HKG: 2196) announced that velinotamig (project code: GR1803), a product licensed-in by its subsidiary Yaopharma, has been conditionally approved by the National Medical Products Administration (NMPA) for the treatment of adult patients with relapsed or refractory multiple myeloma (RRMM) who have previously received at least three prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody. The approval brings a T-cell-engaging bispecific option to one of hematologic oncology&#039;s most difficult-to-treat, heavily pretreated populations.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=77081\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-08-28T13:17:51+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-08-28T13:37:23+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=77081#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=77081\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Fosun Pharma&#8217;s Velinotamig Wins NMPA Conditional Approval for Relapsed or Refractory Multiple Myeloma\",\"datePublished\":\"2026-08-28T13:17:51+00:00\",\"dateModified\":\"2026-08-28T13:37:23+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=77081\"},\"wordCount\":475,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Cancer\",\"Fosun Pharmaceutical\",\"HKG: 2196\",\"Product approvals\",\"SHA: 600196\",\"T cell engager\",\"YaoPharma\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=77081#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=77081\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=77081\",\"name\":\"Fosun Pharma's Velinotamig Wins NMPA Conditional Approval for Relapsed or Refractory Multiple Myeloma - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-08-28T13:17:51+00:00\",\"dateModified\":\"2026-08-28T13:37:23+00:00\",\"description\":\"Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (SHA: 600196, HKG: 2196) announced that velinotamig (project code: GR1803), a product licensed-in by its subsidiary Yaopharma, has been conditionally approved by the National Medical Products Administration (NMPA) for the treatment of adult patients with relapsed or refractory multiple myeloma (RRMM) who have previously received at least three prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody. The approval brings a T-cell-engaging bispecific option to one of hematologic oncology's most difficult-to-treat, heavily pretreated populations.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=77081#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=77081\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=77081#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Fosun Pharma&#8217;s Velinotamig Wins NMPA Conditional Approval for Relapsed or Refractory Multiple Myeloma\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Fosun Pharma's Velinotamig Wins NMPA Conditional Approval for Relapsed or Refractory Multiple Myeloma - Insight, China&#039;s Pharmaceutical Industry","description":"Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (SHA: 600196, HKG: 2196) announced that velinotamig (project code: GR1803), a product licensed-in by its subsidiary Yaopharma, has been conditionally approved by the National Medical Products Administration (NMPA) for the treatment of adult patients with relapsed or refractory multiple myeloma (RRMM) who have previously received at least three prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody. The approval brings a T-cell-engaging bispecific option to one of hematologic oncology's most difficult-to-treat, heavily pretreated populations.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=77081","og_locale":"en_US","og_type":"article","og_title":"Fosun Pharma's Velinotamig Wins NMPA Conditional Approval for Relapsed or Refractory Multiple Myeloma","og_description":"Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (SHA: 600196, HKG: 2196) announced that velinotamig (project code: GR1803), a product licensed-in by its subsidiary Yaopharma, has been conditionally approved by the National Medical Products Administration (NMPA) for the treatment of adult patients with relapsed or refractory multiple myeloma (RRMM) who have previously received at least three prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody. The approval brings a T-cell-engaging bispecific option to one of hematologic oncology's most difficult-to-treat, heavily pretreated populations.","og_url":"https:\/\/flcube.com\/?p=77081","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-08-28T13:17:51+00:00","article_modified_time":"2026-08-28T13:37:23+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=77081#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=77081"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Fosun Pharma&#8217;s Velinotamig Wins NMPA Conditional Approval for Relapsed or Refractory Multiple Myeloma","datePublished":"2026-08-28T13:17:51+00:00","dateModified":"2026-08-28T13:37:23+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=77081"},"wordCount":475,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Cancer","Fosun Pharmaceutical","HKG: 2196","Product approvals","SHA: 600196","T cell engager","YaoPharma"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=77081#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=77081","url":"https:\/\/flcube.com\/?p=77081","name":"Fosun Pharma's Velinotamig Wins NMPA Conditional Approval for Relapsed or Refractory Multiple Myeloma - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-08-28T13:17:51+00:00","dateModified":"2026-08-28T13:37:23+00:00","description":"Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (SHA: 600196, HKG: 2196) announced that velinotamig (project code: GR1803), a product licensed-in by its subsidiary Yaopharma, has been conditionally approved by the National Medical Products Administration (NMPA) for the treatment of adult patients with relapsed or refractory multiple myeloma (RRMM) who have previously received at least three prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody. The approval brings a T-cell-engaging bispecific option to one of hematologic oncology's most difficult-to-treat, heavily pretreated populations.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=77081#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=77081"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=77081#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Fosun Pharma&#8217;s Velinotamig Wins NMPA Conditional Approval for Relapsed or Refractory Multiple Myeloma"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"","_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/77081","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=77081"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/77081\/revisions"}],"predecessor-version":[{"id":77082,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/77081\/revisions\/77082"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=77081"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=77081"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=77081"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}